{"filing":{"accession_number":"0001193125-26-316041","cik":"0000899460","ticker":"MNKD","company_name":"MANNKIND CORP","form":"8-K","filing_date":"2026-07-24","report_date":"2026-07-23","primary_document":"d63182d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/899460/000119312526316041/d63182d8k.htm"},"events":[{"id":20407,"run_id":18368,"accession_number":"0001193125-26-316041","anchor_item_number":"3.02","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"MannKind entered into a Securities Purchase Agreement on July 23, 2026, to sell 10,440,838 shares of common stock at $3.89 per share and 2,412,632 pre-funded warrants at $3.88 per warrant in a private placement, raising approximately $50 million in gross proceeds. The unregistered sale under Section 4(a)(2) of the Securities Act represents a dilutive equity issuance, with proceeds intended for general corporate purposes including a $45 million contingent value rights payment triggered by FDA approval of Furoscix ReadyFlow.","company_name":"MANNKIND CORP","ticker":"MNKD","filing_date":"2026-07-24","form":"8-K","submitted_at":null,"items":[{"id":19758,"accession_number":"0001193125-26-316041","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"MannKind entered into a Securities Purchase Agreement on July 23, 2026, to sell 10,440,838 shares of common stock at $3.89 per share and 2,412,632 pre-funded warrants at $3.88 per warrant in a private placement, raising approximately $50 million in gross proceeds. The filing explicitly discloses this as an unregistered sale under Section 4(a)(2) of the Securities Act, which is the hallmark of a dilutive equity issuance. The company intends to use proceeds for general corporate purposes including a $45 million contingent value rights payment triggered by FDA approval of Furoscix ReadyFlow.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-24T20:03:53.500847+00:00","company_name":"","ticker":null,"filing_date":""},{"id":19759,"accession_number":"0001193125-26-316041","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The primary disclosure in Item 8.01 and the attached press release centers on MannKind's $50 million private placement of common stock and pre-funded warrants to institutional investors. The company is issuing 10,440,838 shares of common stock and pre-funded warrants to purchase 2,412,632 additional shares, representing a dilutive equity issuance. While the Item 8.01 text mentions FDA approval of Furoscix ReadyFlow™, the substantive 8-K disclosure and press release focus on the private placement financing, which is a material capital-raising event typical of dilutive issuances at biopharmaceutical companies.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-24T20:03:53.500847+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":19758,"accession_number":"0001193125-26-316041","item_number":"3.02","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"MannKind entered into a Securities Purchase Agreement on July 23, 2026, to sell 10,440,838 shares of common stock at $3.89 per share and 2,412,632 pre-funded warrants at $3.88 per warrant in a private placement, raising approximately $50 million in gross proceeds. The filing explicitly discloses this as an unregistered sale under Section 4(a)(2) of the Securities Act, which is the hallmark of a dilutive equity issuance. The company intends to use proceeds for general corporate purposes including a $45 million contingent value rights payment triggered by FDA approval of Furoscix ReadyFlow.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-24T20:03:53.500847+00:00","company_name":"MANNKIND CORP","ticker":"MNKD","filing_date":"2026-07-24"},{"id":19759,"accession_number":"0001193125-26-316041","item_number":"8.01","item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"The primary disclosure in Item 8.01 and the attached press release centers on MannKind's $50 million private placement of common stock and pre-funded warrants to institutional investors. The company is issuing 10,440,838 shares of common stock and pre-funded warrants to purchase 2,412,632 additional shares, representing a dilutive equity issuance. While the Item 8.01 text mentions FDA approval of Furoscix ReadyFlow™, the substantive 8-K disclosure and press release focus on the private placement financing, which is a material capital-raising event typical of dilutive issuances at biopharmaceutical companies.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-24T20:03:53.500847+00:00","company_name":"MANNKIND CORP","ticker":"MNKD","filing_date":"2026-07-24"}]}